Clinical trial

A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone

NCT01979679

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-12-01

PhasePHASE3

Study timeline

Study start (unknown)2008-12-01Date precision: month

Registry last updated2013-11-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Interventions

Lurasidone 80 mgDRUG

Lurasidone 120 mgDRUG

Lurasidone 160 mgDRUG

Sponsors & collaborators

University of California, Irvinelead sponsor

Dainippon Sumitomo Pharma Americacollaborator

Mapped research locations

OrangeCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01979679 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.